Beta-blockers (All routes except ocular) (versus unexposed) updated on 12-17-2024

Fetal distress

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14079
R55424		 Gandjbakhch - Beta-blockers, 2018 Neonatal fetal distress during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 0.95 [0.04;24.78] C 0/13   1/37 1 13
ref
S13811
R54141		 Chan - Labetalol, 2010 Fetal distress during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 3.14 [1.01;9.74] C 11/32   6/42 17 32
ref
S14183
R55595		 Yassen - Acebutolol, 1992 Acute fetal distress (lasting alteration of fetal heart recording tracings: micro-oscillating appearance, bradycardia) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 30.33 [1.39;660.79] C 6/11   0/11 6 11
ref
Total 3 studies 3.86 [0.96;15.42] 24 56
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Gandjbakhch - Beta-blockers, 2018Gandjbakhch - Beta-blockers, 2018 0.95[0.04; 24.78]11316%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Chan - Labetalol, 2010Chan - Labetalol, 2010 3.14[1.01; 9.74]173267%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: lowROB reporting: moderate Yassen - Acebutolol, 1992Yassen - Acebutolol, 1992 30.33[1.39; 660.79]61117%ROB confusion: criticalROB selection: unclearROB classification: unclearROB missing: lowROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 21% 3.86[0.96; 15.42]24560.2100.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.86[0.96; 15.42]245621%NAGandjbakhch - Beta-blockers, 2018 Chan - Labetalol, 2010 Yassen - Acebutolol, 1992 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 6.09[0.81; 45.95]234345%NAChan - Labetalol, 2010 Yassen - Acebutolol, 1992 2 unexposed, sickunexposed, sick 0.95[0.04; 24.78]113 -NAGandjbakhch - Beta-blockers, 2018 1 Tags Adjustment   - No  - No 3.86[0.96; 15.42]245621%NAGandjbakhch - Beta-blockers, 2018 Chan - Labetalol, 2010 Yassen - Acebutolol, 1992 3 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 6.09[0.81; 45.95]234345%NAChan - Labetalol, 2010 Yassen - Acebutolol, 1992 2   - Only cardiac indications other than ...  - Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 0.95[0.04; 24.78]113 -NAGandjbakhch - Beta-blockers, 2018 1 MatchedMatched 6.09[0.81; 45.95]234345%NAChan - Labetalol, 2010 Yassen - Acebutolol, 1992 2 All studiesAll studies 3.86[0.96; 15.42]245621%NAGandjbakhch - Beta-blockers, 2018 Chan - Labetalol, 2010 Yassen - Acebutolol, 1992 30.2100.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 6.09[0.81; 45.95]234345%NAChan - Labetalol, 2010 Yassen - Acebutolol, 1992 2 unexposed, sick controlsunexposed, sick controls 0.95[0.04; 24.78]113 -NAGandjbakhch - Beta-blockers, 2018 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (Fetal heart rate abnormalities) 3.23[0.90; 11.11]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT5 metaPregmetaPreg 3.86[0.96; 15.42]21%56----Gandjbakhch - Beta-blockers, 2018 Chan - Labetalol, 2010 Yassen - Acebutolol, 1992 30.510.01.0